34 results about "Lipid level" patented technology

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.

Provided are a GLP-1GIP analog, an FGF21 protein, a trifunctional protein, and use thereof. The trifunctional protein comprises the GLP-1 / GIP analog and the FGF21 protein. Further provided is use of the GLP-1 / GIP analog, the FGF21 protein, and the trifunctional protein in the preparation of a drug for preventing and / or treating diseases related to GLP-1, GIP, and / or FGF21. The provided GLP-1 / GIP analog, FGF21 protein, and trifunctional protein can synergistically regulate blood glucose and lipid levels in vivo, meet multiple needs in patients with type 2 diabetes, including lowering blood glucose, alleviating hepatic steatosis, promoting weight loss, ameliorating circulating lipid metabolism disorder, etc., and have better biological safety and tolerability and longer in vivo half-lives.

The invention discloses a GLP-1 GIP analogue, an FGF21 protein, a three-function protein and an application thereof. The trifunctional protein comprises a GLP-1 / GIP analogue and an FGF21 (Fibroblast Growth Factor 21) protein. The invention also discloses application of the GLP-1 / GIP analogue, the FGF21 protein and the three-function protein in preparation of medicines for preventing and / or treating diseases related to GLP-1, GIP and / or FGF21. The GLP-1 / GIP analogue, the FGF21 protein and the three-function protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, meet multiple requirements of patients with type 2 diabetes for reducing blood sugar, relieving liver fatty degeneration, reducing weight, improving circulating lipid metabolism disorder and the like, and are better in biological safety and tolerance and longer in in-vivo half-life period.

The invention provides a composition comprising a plant or fungal extract in combination with a xanthone compound. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea. The composition may comprise (a) a xanthone compound according to formula (I), or a pharmaceutically or cosmetically acceptable salt, prodrug, solvate, tautomer or stereoisomer thereof; and (b) a plant or fungal extract selected from extracts of plants belonging to the genus Arctostaphylos, Hedera, Ilex, Fragaria and Rubus and extracts of the fungus Wolfiporia, (I) where each of R1 to R8 are described herein.

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

To provide plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1.SOLUTION: The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicines, and particularly relates to a daphniphyllum calycinum extract compound, an extraction method thereof and application of the daphniphyllum calycinum extract compound in preparation of a medicine for preventing or treating non-alcoholic fatty liver diseases. A natural compound with a novel structure is obtained from daphniphyllum calycinum for the first time, a preparation method of the compound is provided, activity research is carried out on the compound, and experimental data shows that the compound is low in cytotoxicity and has no obvious cytotoxicity to normal cells, and the compound can be used for preparing the compound by inhibiting expression of fatty acid synthetases ACC, ACLY and FAS. The compound inhibits the de novo synthesis of fatty acid in cells, thereby inhibiting the accumulation of lipid droplets in the cells and reducing the lipid level in the cells, and has wide application prospects in the field of preparation of drugs for preventing or treating non-alcoholic fatty liver diseases.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

The present invention relates to an RNAi agent for inhibiting SCAP gene expression, a preparation method and use thereof, the RNAi agent being capable of inhibiting SCAP gene expression to treat SCAP gene related diseases and disorders, such as treatment of elevated blood lipid levels.

The invention relates to application of biochanin A in preparation of medicines for preventing or treating liver diseases or liver injury. The biochanin A has the characteristics of remarkable curative effect, safety, reliability, small toxic and side effects and the like when being used for treating the non-alcoholic fatty liver disease; the biochanin A reduces the accumulation of lipid peroxidation products and reduces the neutral lipid level by inhibiting the iron accumulation of liver tissues, so that the fatty degeneration of the liver and the liver injury are relieved. Starting from a monomeric compound, the compound intervenes in the non-alcoholic fatty liver disease, the levels of ALT, AST and TC in serum of a model mouse and TG in liver tissue are remarkably reduced, liver adiposis and inflammatory injury are relieved, and the compound has a good clinical application prospect.

The invention provides a composition comprising a plant or fungal extract in combination with a phenol compound. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea. The composition may comprise (a) a phenol compound according to formula (I), or a pharmaceutically or cosmetically acceptable salt, prodrug, solvate, tautomer or stereoisomer thereof; and (b) a plant or fungal extract selected from extracts of plants belonging to the genus Arctostaphylos, Fragaria, Garcinia, Hedera, Ilex, and Rubus, and extracts of the fungus Wolfiporia, (I) where each of R1 to R5 and -L- are as described herein.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. 20 24 20 26 17 22 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 1 7 2 2 A p r 2 0 2 4

The invention discloses an application of corosolic acid in preparation of a medicine for preventing or treating a non-alcoholic fatty liver disease, and relates to the technical field of medicines. The research finds that corosolic acid improves the treatment mechanism of the non-alcoholic fatty liver disease from the perspective of dynamic balance of intestinal flora, and in addition, corosolic acid has the effects of reducing the in-vivo lipid level and protecting the liver at the same time; the corosolic acid is used for improving the non-alcoholic fatty liver disease by playing a role through the hepatic intestinal axis, balancing the relative expression abundance of intestinal flora and regulating a metabolic pathway, so that the intestinal injury is reduced, the effect of protecting the liver is played, and a foundation is laid for later development of medicines for treating the non-alcoholic fatty liver disease by corosolic acid.

Pharmaceutical compositions comprising a C1-C4 alkyl ester azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), di-isopropyl azelate (DiPA), di-isobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and methods of, inter alia, improving abnormal lipid levels and treating or preventing dyslipidemias and / or diseases of conditions associated therewith comprising administering to a subject such pharmaceutical compositions, are provided.

The invention provides a composition comprising oleanolic acid and the salts, prodrug and solvates thereof; and one or more compounds selected from the following group: ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea.

The invention belongs to the technical field of dermatan sulfate application, and particularly relates to application of dermatan sulfate in promotion of cholesterol excretion. The cholesterol excretion promoting effect of dermatan sulfate is discussed through in-vivo and in-vitro experiments, and results show that dermatan sulfate has the effect of promoting cholesterol excretion of liver cells, not only can reduce blood fat and liver lipid and promote excretion of cholesterol to excrement, but also can inhibit expression of ASGR1, further up-regulates LXR alpha, and has the effect of promoting cholesterol excretion of liver cells. The expression of ABCA1 and ABCG5 transporters is improved to promote cholesterol excretion and reduce the in-vivo lipid level. Therefore, dermatan sulfate is a potential medicine for promoting cholesterol excretion, a new thought is provided for development of a targeted ASGR1 medicine for promoting cholesterol excretion, and a theoretical basis is provided for treatment of cardiovascular diseases such as hypercholesterolemia and the like.

Disclosed herein are compositions, constructs, cassettes, vectors, cells, nucleic acids, peptides, proteins, protocols and methods for reducing cholesterol and lipid buildup in mammalian subjects, via gene and / or cell therapeutic treatments. In many embodiments, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods may help to reduce lipid levels in mammals. In one embodiment, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods are useful in reducing lipid build-up, especially cholesterol, in liver cells.

The present invention relates to Bifidobacterium longum subsp. longum C-5 with the efficacy of regulating body weight and its application. The taxonomic naming of the Bifidobacterium longum subsp. longum C-5 is Bifidobacterium longum subsp. longum , and the preservation number is GDMCC No: 64542, and the preservation date is April 22, 2024. This strain can improve the efficacy of obesity, hyperlipidemia, or inflammatory bowel disease caused by a high-fat diet through various action mechanisms such as regulating blood glucose and lipid levels, improving oxidative stress response, regulating adipose tissue metabolism, and alleviating liver injury or colonic tissue inflammation, significantly improving the symptoms of metabolic disorders, and providing coping strategies and reference basis for the prevention and treatment of obesity.

This invention provides nanoparticles with plaque-targeting function, their preparation method, and their application in the preparation of anti-atherosclerotic drugs, belonging to the field of composite nanomaterials technology. The plaque-targeting nanoparticles provided by this invention comprise a core and a shell. The core is ZIF-8 nanoparticles loaded with neoindocyanine green, and the shell is arginine-modified polydopamine; the surface of the shell is modified with hyaluronic acid. The plaque-targeting nanoparticles provided by this invention can regulate lipid levels by simultaneously intervening in multiple pathways, providing anti-inflammatory effects, protecting damaged endothelial cells, and enabling low-temperature (42-45℃) photothermal therapy combined with anti-nlrp3 therapy. This treats atherosclerosis by regulating PCSK9 pathway-induced lipid accumulation and repairing damaged endothelial cells.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

The present invention provides a pharmaceutical composition comprising a C1-C4 alkyl azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), diisopropyl azelate (DiPA), diisobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), such as dioctyl azelate (DEA), dimethyl azelate (DMA), diisopropyl azelate (DiPA), diisobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and, in particular, methods of ameliorating abnormal lipid levels and treating or preventing dyslipidemia or a disease or condition associated with dyslipidemia comprising administering such pharmaceutical compositions to a subject.

This invention relates to the field of biomedical technology, disclosing extracellular vesicles derived from Poria cocos and their application in the development and preparation of drugs for the prevention or treatment of metabolic-associated steatohepatitis (MAS). The drugs improve liver tissue morphology and pathological lesions, regulate serum and liver lipid levels and inflammatory factor levels, and regulate mitochondrial structure and function, including alleviating mitochondrial ultrastructural damage, increasing the number of autophagosomes, improving oxidative stress and energy metabolism, promoting the expression of mitochondrial autophagy-related proteins, and reducing the production and efflux of Ox-mtDNA, thereby inhibiting the expression of NLRP3 inflammasome-related proteins. These drugs can improve MAS and provide a new direction for the development and research of drugs for the prevention and treatment of MAS.

The invention relates to the technical field of health care products, in particular to a composition with a uric acid reducing effect and a preparation method thereof. The composition with the uric acid reducing effect is prepared from the following components in parts by mass: 5 to 10 parts of N-acetylglucosamine, 2 to 5 parts of honeysuckle flower polysaccharide and 1 to 3 parts of radix pseudostellariae oligosaccharide. The composition provided by the invention has the effects of inhibiting xanthine oxidase, resisting inflammation, regulating intestinal flora, improving immunity, inhibiting creatinine level rise, relieving oxidative damage, reducing lipid level and the like, so that generation of uric acid is inhibited and reduced, and chronic damage to kidneys, cardiovascular systems and the like is reduced.

The present invention relates to the polyherbal composition for optimum vascular activity and cardiac health. The Invention also provides its method of preparation. The composition exhibits beneficial effects in regulating dyslipidaemia, controlling and reducing arterial fat deposition along with reducing elevated levels of serum cholesterol, triglycerides and associated atherosclerosis. The composition also regulates lipid levels and promotes cardiovascular health, as well as improves overall cardiac function.

The present invention generally relates to novel multi - agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, such as those that can be alleviated by control of weight loss, plasma glucose and lipid levels, insulin levels, and / or insulin secretion, positive inotropic action, reduction of catabolism, deceleration of gastric emptying, and prevention of neurodegeneration. Such conditions and disorders include, but are not limited to, food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels and / or insulin secretion, positive inotropic action, reduction of catabolism, deceleration of gastric emptying, obesity, diabetes and diabetes - related conditions, control of liver fat - related inflammation and damage. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, and rare genetic disorders of obesity, such as Prader - Willi syndrome, critical care, insulin resistance and its disorders, such as polycystic ovary syndrome, obesity, all types of diabetes including type 1, type 2 and gestational diabetes, and CNS disorders, such as prevention of neurodegeneration, depression, alcoholism, Alzheimer's disease and Parkinson's disease, and non - alcoholic steatohepatitis (NASH).

The invention belongs to the technical field of microorganisms, preparations and efficient culture, and particularly relates to a bacterial strain for lowering lipid and improving metabolism-related fatty liver diseases, a preparation, application and an efficient culture method, the bacterial strain cultured and preserved and a corresponding product can be used for lowering lipid and improving metabolism-related fatty liver diseases, and by promoting secretion of pantothenic acid, the lipid-lowering and metabolism-related fatty liver diseases can be improved. According to the present invention, the liver lipid level is reduced, the liver injury is relieved, the metabolism-related fatty liver disease is treated, the metabolic disorder caused by the high fat diet is improved, the levels of inflammatory factors TNF-alpha and IL-6 are reduced, the LPS production is reduced, the liver inflammatory reaction is reduced, and the lipid level in the body is reduced by reducing the TC, TG and L-DLC in the plasma and the liver and recovering the AST and ALT levels in the liver, such that the in-vivo lipid level is reduced, the liver injury is relieved, the metabolism-related fatty liver disease is treated, and the metabolic disorder caused by the high fat diet is improved; in addition, a certain amount of inonotus obliquus polysaccharide is added into the culture medium, so that the yield of the strain is remarkably increased, and the growth speed of the logarithmic phase is promoted.